Stockscreener 앱 받기
2.40
0.00%
0.00
시간 외 거래:
2.40
전일 마감가:
$2.40
열려 있는:
$2.42
하루 거래량:
974.01K
Relative Volume:
0.28
시가총액:
$432.21M
수익:
$850.00K
순이익/손실:
$-68.17M
주가수익비율:
-5.8309
EPS:
-0.4116
순현금흐름:
$-53.29M
1주 성능:
+3.90%
1개월 성능:
+15.94%
6개월 성능:
-60.00%
1년 성능:
-20.53%
1일 변동 폭
$2.32
$2.43
1주일 범위
$2.24
$2.52
52주 변동 폭
$1.61
$6.88
Compass Therapeutics Inc Stock (CMPX) Company Profile
명칭
Compass Therapeutics Inc
전화
617-500-8099
주소
80 GUEST STREET, BOSTON
Compare CMPX vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CMPX
Compass Therapeutics Inc
|
2.40 | 425.01M | 850.00K | -68.17M | -53.29M | -0.4116 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Compass Therapeutics Inc Stock (CMPX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-13 | 개시 | Craig Hallum | Buy |
| 2026-01-05 | 개시 | William Blair | Outperform |
| 2025-12-03 | 개시 | Canaccord Genuity | Buy |
| 2025-12-03 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-12-03 | 개시 | Citizens JMP | Mkt Outperform |
| 2025-07-01 | 재개 | Raymond James | Outperform |
| 2025-04-02 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-02-24 | 개시 | Guggenheim | Buy |
| 2025-02-19 | 개시 | Piper Sandler | Overweight |
| 2024-12-23 | 개시 | D. Boral Capital | Buy |
| 2024-11-15 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-09-16 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2023-01-31 | 개시 | Jefferies | Buy |
| 2023-01-27 | 개시 | Stifel | Buy |
| 2022-05-23 | 재개 | H.C. Wainwright | Buy |
| 2022-03-15 | 개시 | Ladenburg Thalmann | Buy |
| 2022-01-19 | 개시 | B. Riley Securities | Buy |
| 2021-12-22 | 개시 | Raymond James | Outperform |
| 2021-12-20 | 개시 | SVB Leerink | Outperform |
| 2021-12-15 | 개시 | Wedbush | Outperform |
모두보기
Compass Therapeutics Inc 주식(CMPX)의 최신 뉴스
CMPX Stock Has Retail Buzzing Ahead Of High-Stakes Cancer Drug Trial Update - Stocktwits
Compass (CMPX) Session: Finishes 4.23% Lower at $2.38; Technical Setup: the Supplied Trading Band Runs From $2.26 to $2.50 in the Current UpdateDollar Neutral Pair - vinanet.vn
NEXTBio Capital Management LP's Compass Therapeutics Inc(CMPX) Holding History - GuruFocus
Compass Therapeutics Inc. (CMPX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Compass (CMPX) Earnings Data Review: The EPS Result Is Below Expectation in the Available Record; Investor Response: Shares Close 3.46% Higher in the Latest SessionCore Business Growth - vinanet.vn
Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Stifel Maintains Compass Therapeutics(CMPX.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Compass Therapeutics And 2 Other Promising Penny Stocks For Your Watchlist - simplywall.st
We're Not Very Worried About Compass Therapeutics' (NASDAQ:CMPX) Cash Burn Rate - Moomoo
Compass Therapeutics (CMPX) Climbs 3.26% to $2.22, Approaches Key ResistanceMAMA Signal - dars.gov.et
HC Wainwright Issues Pessimistic Estimate for CMPX Earnings - MarketBeat
Compass Therapeutics Inc. (CMPX) Stock News Today - TradingKey
Compass Therapeutics (NASDAQ:CMPX) Rating Lowered to Strong Sell at Wall Street Zen - MarketBeat
Compass Therapeutics (NASDAQ:CMPX) Posts Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
A Quick Look at Today's Ratings for Compass Therapeutics(CMPX.US), With a Forecast Between $6 to $7 - Moomoo
Compass Therapeutics (NASDAQ:CMPX) Price Target Raised to $6.00 at Piper Sandler - MarketBeat
Compass Therapeutics Inc. (CMPX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Compass Therapeutics (CMPX) Gains 4.5% to $2.08 as Buyers Defend Key Support LevelInstitutional Flow Picks - dars.gov.et
Compass Therapeutics, Inc. Stock 12‑Month Price Target Raised to $8.67, Implies 359% Upside - TradingView
Compass Therapeutics, Inc. Q2 2026 Financial Results: Balance Sheet, Losses & Key Highlights from CMPX 10-Q Filing - Minichart
Form 8K Compass Therapeutics, Inc. For: 6 August By Investing.com - Investing.com Nigeria
Compass Therapeutics, Inc. 2026: Revenue ($25.25M), Net income ($25.15M), EPS ($0.13) — 10-Q Summary - tradingview.com
Compass Therapeutics (NASDAQ: CMPX) details Q2 loss and BTC trial gains - stocktitan.net
CMPX: Strong pipeline progress and solid cash position support continued clinical development - TradingView
Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update - Yahoo Finance
Compass Therapeutics Q2 2026 earnings: Pipeline spending widens the net loss - TradingKey
Compass Therapeutics, Inc. (CMPX) Investigation: Bronstein, Gewir - The National Law Review
Compass Therapeutics (CMPX) Projected to Announce Earnings on Monday - MarketBeat
Compass Therapeutics Inc. (CMPX) Institutional Confidence - TradingKey
CMPX Q2'26 Earnings: revenue estimate is (600.00K USD) - TradingView
CMPX|Compass Therapeutics Inc.|Price:1.885|Chg%:-0.025 - TradingKey
Compass Therapeutics, Inc. $CMPX Shares Sold by Rock Springs Capital Management LP - MarketBeat
Compass Therapeutics Inc. (CMPX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Compass Therapeutics Inc. (CMPX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Compass Therapeutics Inc. (CMPX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CMPX|Compass Therapeutics Inc.|Price:2.080| - TradingKey
TradingKey - TradingKey
Compass Therapeutics Inc. (CMPX) Income Statement - TradingKey
Compass Therapeutics Inc. (CMPX) Balance Sheet - TradingKey
CMPX|Compass Therapeutics Inc.|Price:2.092|Chg%:+0.022 - TradingKey
Compass Therapeutics, Inc. Revenue Breakdown – NASDAQ:CMPX - TradingView
CMPX Q1 2026 Earnings: Narrow EPS Beat as Clinical-Stage Biotech Continues Pipeline DevelopmentStrong Earnings Momentum - po-news-eg.net
Compass Therapeutics Inc. (CMPX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Monashee Investment Management LLC Sells 741,135 Shares of Compass Therapeutics, Inc. $CMPX - MarketBeat
Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Compass Therapeutics (CMPX) Slides 2.38% as Support Levels Come Into FocusStock Picks - dars.gov.et
Enterprise value to EBIT forward of Compass Therapeutics, Inc. – NASDAQ:CMPX - TradingView
Compass Therapeutics (CMPX) Jefferies Global Healthcare Conference 2026 Summary - Quartr
Compass Therapeutics to present Phase 2/3 tovec... - Pluang
Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026 - The Manila Times
Compass Therapeutics’ COMPANION-002 Biliary Tract Cancer Study Accepted for Oral Presentation at ESMO 2026 - Quiver Quantitative
Compass Therapeutics Inc (CMPX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.00%
3.22%
자본화:
|
볼륨(24시간):